Dr. Richmond Wolf to Chair Arrowhead Research Corporation's Advisory

Dr. Richmond Wolf to Chair Arrowhead Research Corporation's Advisory Board

    Business Editors/Technology Writers/High-Tech Editors

    PASADENA, Calif.--(BUSINESS WIRE)--March 29, 2005--Arrowhead Research Corporation (NASDAQ:ARWR) (NASDAQ:ARWRW) announced today that Dr. Richmond Wolf, Director of the Office of Technology Transfer at the California Institute of Technology (Caltech), has agreed to join Arrowhead as Chairman of the Advisory Board. In addition, Dr. Wolf will serve as a key consultant to the Company, assisting Arrowhead and its subsidiaries with technology development and identifying strategic opportunities.
    "Dr. Wolf has the technical knowledge and business acumen to help Arrowhead expand our commercialization and research programs," said R. Bruce Stewart, Arrowhead's President. "We expect that his deep experience and broad-based exposure to technology transfer and product development will be particularly valuable."
    As the Director of the Caltech Office of Technology Transfer, Dr. Wolf is responsible for the management and licensing of the intellectual property developed at Caltech and the Jet Propulsion Laboratory (JPL), which portfolios include over 2000 issued and pending patents. While at Caltech, Dr. Wolf has worked with technology start-up companies from Caltech and JPL in areas of business and product development, and he is a co-founder of two companies.
    Dr. Wolf is a member of the Board of Directors of Alexandria Real Estate Equities (NYSE:ARE) and he is or has been a member of the advisory board of ITU Ventures, Oak Grove Systems, the Los Angeles Regional Technology Alliance, and the Egg Factory. He has been an observer on the boards of several other start-ups. Dr. Wolf is a graduate of Princeton University cum laude, received a Ph.D. from Caltech, and is also a registered patent agent.

    About Arrowhead Research Corporation

    Arrowhead Research is a nanotechnology company structured to bring together a diverse and innovative mix of technologies, rights to a broad suite of intellectual property, and some of the most respected minds in this dynamic field. Arrowhead is a development-stage company, and its business model is based on three strategic components:

--	The Commercialization Program: Arrowhead forms or acquires majority-owned subsidiary companies pursuing products based on nanotechnology in high-growth technology markets.
--	The Research Program: Arrowhead funds nanoscience research at universities in exchange for exclusive rights to license the technology.
--	The Intellectual Property Toolbox: Arrowhead acquires licenses, and sublicenses patents and other intellectual property in nanotechnology.

    Arrowhead Research operates four majority-owned subsidiary companies:

    -- Aonex Technologies, Inc. is developing and commercializing
    proprietary semiconductor nanomaterial technology.

    -- Insert Therapeutics, Inc. is developing and commercializing
    proprietary nanometer-sized therapeutics.

    -- Nanotechnica, Inc. is developing capabilities for
    mass-production of a variety of different, proprietary
    nanoscale devices and systems.

    -- Calando, Inc. is developing nanostructures for delivery of RNA
    interference.

    Arrowhead is also funding three research efforts in nanotechnology at Caltech in the areas of nanomaterials, nanoelectronics, and nanobiomolecular tools.

    Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

    This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including, without limitation, our developmental stage and limited operating history, our ability to successfully develop products, rapid technological change in our markets, demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, Registration Statement on Form S-3, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

--30--MR/la*

CONTACT: Arrowhead Research Corporation R. Bruce Stewart, 626-792-5549 bruce@arrowres.com

KEYWORD: CALIFORNIA INDUSTRY KEYWORD: BIOTECHNOLOGY MANUFACTURING MANAGEMENT CHANGES SOURCE: Arrowhead Research Corporation

Copyright Business Wire 2005